New research shows a novel pill is helping people with advanced pancreatic cancer live longer. Researches call it a "very ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Roswell Park researchers at ASCO 2026 report GLP-1 links to breast cancer risk, CAR T safety in older myeloma patients, and ...

Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J plans to seek expanded approvals for Erleada May 31 (Reuters) - Johnson & Johnson's (JNJ.N), ...

The highly anticipated results of a clinical trial for the pill, daraxonrasib, have been released, giving doctors hope for ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

The foundation asked for $6.4 million over four years in Budget 2026 to fund two regional pilots for the early detection screening of prostate cancer.

The NHS is set to reject a national rollout of a blood test for cancer despite it diagnosing four times as many people with the disease as standard screening.